| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d4dc8f7db08607c344fa0afbad4f8e3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 |
| filingDate |
2018-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab83b35a43cd34c8d3a96b97f4148a3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95ec5c0dbea24599dac5e9838c830f5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_282bcf8f94b38e53f7da899a094aa62c |
| publicationDate |
2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201928057-A |
| titleOfInvention |
Nucleic acid, pharmaceutical composition and conjugate containing the same, and preparation method, use and kit |
| abstract |
The invention provides an siRNA for inhibiting the expression of a hepatitis B virus gene, a pharmaceutical composition and a conjugate containing the siRNA. Each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA contains a sense strand and an antisense strand, and the sense strand contains a nucleotide sequence 1, which is in accordance with SEQ. The nucleotide sequence shown in ID NO: 155 is equal in length and does not differ by more than 3 nucleotides. The antisense strand contains nucleotide sequence 2, which is identical to SEQ ID NO: 156. The nucleotide sequences shown are of equal length and no more than 3 nucleotide differences. The siRNA, the pharmaceutical composition and the conjugate provided by the present invention can effectively treat and / or prevent hepatitis B. |
| priorityDate |
2017-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |